vs

Side-by-side financial comparison of Immunovant, Inc. (IMVT) and PRECISION OPTICS CORPORATION, INC. (POCI). Click either name above to swap in a different company.

Immunovant, Inc. is the larger business by last-quarter revenue ($8.4M vs $7.4M, roughly 1.1× PRECISION OPTICS CORPORATION, INC.). PRECISION OPTICS CORPORATION, INC. runs the higher net margin — -24.2% vs -899.0%, a 874.8% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 62.8%).

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

Century Precision Optics is an American lens manufacturing firm. It was founded in 1948 in North Hollywood, California as Century Photo Optics. Steven Manios Sr. purchased the company in 1973 and created many of the optics. Century Optics makes a variety of digital, broadcast, projection, and industrial lenses. They have offices in Hauppauge, New York and Van Nuys, California.

IMVT vs POCI — Head-to-Head

Bigger by revenue
IMVT
IMVT
1.1× larger
IMVT
$8.4M
$7.4M
POCI
Growing faster (revenue YoY)
IMVT
IMVT
+78.0% gap
IMVT
140.7%
62.8%
POCI
Higher net margin
POCI
POCI
874.8% more per $
POCI
-24.2%
-899.0%
IMVT

Income Statement — Q4 FY2024 vs Q2 FY2026

Metric
IMVT
IMVT
POCI
POCI
Revenue
$8.4M
$7.4M
Net Profit
$-75.3M
$-1.8M
Gross Margin
2.8%
Operating Margin
-896.2%
-23.6%
Net Margin
-899.0%
-24.2%
Revenue YoY
140.7%
62.8%
Net Profit YoY
-26.7%
-83.6%
EPS (diluted)
$-0.50
$-0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMVT
IMVT
POCI
POCI
Q4 25
$7.4M
Q3 25
$6.7M
Q2 25
$6.2M
Q1 25
$4.2M
Q4 24
$4.5M
Q3 24
$4.2M
Q2 24
$4.7M
Q1 24
$8.4M
$5.2M
Net Profit
IMVT
IMVT
POCI
POCI
Q4 25
$-1.8M
Q3 25
$-1.6M
Q2 25
$-1.4M
Q1 25
$-2.1M
Q4 24
$-969.7K
Q3 24
$-1.3M
Q2 24
$-1.4M
Q1 24
$-75.3M
$-317.1K
Gross Margin
IMVT
IMVT
POCI
POCI
Q4 25
2.8%
Q3 25
14.2%
Q2 25
12.9%
Q1 25
10.0%
Q4 24
23.6%
Q3 24
26.6%
Q2 24
21.7%
Q1 24
35.5%
Operating Margin
IMVT
IMVT
POCI
POCI
Q4 25
-23.6%
Q3 25
-23.9%
Q2 25
-21.9%
Q1 25
-48.7%
Q4 24
-20.1%
Q3 24
-29.7%
Q2 24
-28.8%
Q1 24
-896.2%
-4.9%
Net Margin
IMVT
IMVT
POCI
POCI
Q4 25
-24.2%
Q3 25
-24.5%
Q2 25
-22.7%
Q1 25
-50.1%
Q4 24
-21.4%
Q3 24
-31.2%
Q2 24
-29.9%
Q1 24
-899.0%
-6.0%
EPS (diluted)
IMVT
IMVT
POCI
POCI
Q4 25
$-0.23
Q3 25
$-0.21
Q2 25
$-0.19
Q1 25
$-0.30
Q4 24
$-0.15
Q3 24
$-0.21
Q2 24
$-0.23
Q1 24
$-0.50
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMVT
IMVT
POCI
POCI
Cash + ST InvestmentsLiquidity on hand
$635.4M
$881.5K
Total DebtLower is stronger
$1.6M
Stockholders' EquityBook value
$617.8M
$9.3M
Total Assets
$666.4M
$22.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMVT
IMVT
POCI
POCI
Q4 25
$881.5K
Q3 25
$1.4M
Q2 25
$1.8M
Q1 25
$2.5M
Q4 24
$212.4K
Q3 24
$635.6K
Q2 24
$405.3K
Q1 24
$635.4M
$925.1K
Total Debt
IMVT
IMVT
POCI
POCI
Q4 25
$1.6M
Q3 25
$1.8M
Q2 25
$1.9M
Q1 25
$2.1M
Q4 24
$2.1M
Q3 24
$2.1M
Q2 24
$2.2M
Q1 24
$2.3M
Stockholders' Equity
IMVT
IMVT
POCI
POCI
Q4 25
$9.3M
Q3 25
$10.9M
Q2 25
$12.3M
Q1 25
$13.2M
Q4 24
$9.5M
Q3 24
$10.1M
Q2 24
$10.1M
Q1 24
$617.8M
$11.3M
Total Assets
IMVT
IMVT
POCI
POCI
Q4 25
$22.9M
Q3 25
$22.4M
Q2 25
$19.8M
Q1 25
$19.6M
Q4 24
$17.5M
Q3 24
$17.2M
Q2 24
$16.9M
Q1 24
$666.4M
$18.3M
Debt / Equity
IMVT
IMVT
POCI
POCI
Q4 25
0.17×
Q3 25
0.16×
Q2 25
0.16×
Q1 25
0.16×
Q4 24
0.22×
Q3 24
0.21×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMVT
IMVT
POCI
POCI
Operating Cash FlowLast quarter
$-59.7M
$-256.1K
Free Cash FlowOCF − Capex
$-59.8M
FCF MarginFCF / Revenue
-714.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMVT
IMVT
POCI
POCI
Q4 25
$-256.1K
Q3 25
$78.2K
Q2 25
$-569.2K
Q1 25
$-1.9M
Q4 24
$-786.8K
Q3 24
$-318.6K
Q2 24
$-976.0K
Q1 24
$-59.7M
$-214.2K
Free Cash Flow
IMVT
IMVT
POCI
POCI
Q4 25
Q3 25
Q2 25
$-615.5K
Q1 25
$-2.0M
Q4 24
$-816.6K
Q3 24
$-343.0K
Q2 24
$-987.6K
Q1 24
$-59.8M
$-322.7K
FCF Margin
IMVT
IMVT
POCI
POCI
Q4 25
Q3 25
Q2 25
-10.0%
Q1 25
-47.8%
Q4 24
-18.0%
Q3 24
-8.2%
Q2 24
-20.9%
Q1 24
-714.4%
-6.2%
Capex Intensity
IMVT
IMVT
POCI
POCI
Q4 25
Q3 25
Q2 25
0.7%
Q1 25
3.0%
Q4 24
0.7%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
1.8%
2.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMVT
IMVT

Segment breakdown not available.

POCI
POCI

Systems Manufacturing$5.2M70%
Other$1.1M15%
Ross Optical Industries$1.0M14%

Related Comparisons